Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v5-FR | Version v4-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2017-11-24 | 2017-11-24 |
| Drug Identification Number | 02334844 | 02334844 |
| Brand name | AZITHROMYCIN FOR INJECTION, USP | AZITHROMYCIN FOR INJECTION, USP |
| Common or Proper name | AZITHROMYCIN | AZITHROMYCIN |
| Company Name | HOSPIRA HEALTHCARE ULC | HOSPIRA HEALTHCARE ULC |
| Ingredients | AZITHROMYCIN | AZITHROMYCIN |
| Strength(s) | 500MG | 500MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS | INTRAVENOUS |
| Packaging size | 10x500mg | 10x500mg |
| ATC code | J01FA | J01FA |
| ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2018-03-06 | 2018-03-06 |
| Actual start date | ||
| Estimated end date | Unknown | Unknown |
| Actual end date | 2017-09-30 | 2017-09-30 |
| Shortage status | Avoided shortage | Avoided shortage |
| Tier 3 Status | No | No |
| Company comments | Product importation is currently on hold in accordance with new Health Canada terms and conditions related to its manufacturing site of origin. This importation hold is on future lots and does not impact any existing inventories or those already distributed on the market. The inventory on hand remains available and will be allocated to customers based on their monthly average order quantity. Alternate suppliers have been contacted in order to minimize potential supply disruptions. | Product importation is currently on hold in accordance with new Health Canada terms and conditions related to its manufacturing site of origin. This importation hold is on future lots and does not impact any existing inventories or those already distributed on the market. The inventory on hand remains available and will be allocated to customers based on their monthly average order quantity. Alternate suppliers have been contacted in order to minimize potential supply disruptions. |
| Health Canada comments |